Boston Scientific Corporation announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed Field Ablation System*, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation.
